{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:20:48Z","timestamp":1791937248527,"version":"4.3.4"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.eclinm.2024.102988","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T19:46:03Z","timestamp":1736538363000},"page":"102988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols"],"prefix":"10.1016","volume":"79","author":[{"given":"Moreno","family":"Ursino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5207-3864","authenticated-orcid":false,"given":"Jan","family":"Rekowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9311-6920","authenticated-orcid":false,"given":"Munyaradzi","family":"Dimairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Solovyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Wen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney H.","family":"Coschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R. Jeffry","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Golub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn S.","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kholmanskikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5228-3255","authenticated-orcid":false,"given":"Andrew","family":"Kightley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Mander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynley V.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Matcham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4113-2726","authenticated-orcid":false,"given":"Dhrusti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija Rerhou","family":"Rantell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn P.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Rouhifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-2514","authenticated-orcid":false,"given":"Christina","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2024.102988_bib1","doi-asserted-by":"crossref","first-page":"e068173","DOI":"10.1136\/bmjopen-2022-068173","article-title":"SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol","volume":"13","author":"Espinasse","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12916-023-02937-0","article-title":"Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study","volume":"21","author":"Solovyeva","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.annonc.2022.09.158","article-title":"Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022","volume":"34","author":"Araujo","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102988_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102020","article-title":"Assessing the reporting quality of early phase dose-finding trial protocols: a methodological review","volume":"60","author":"Villacampa","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2024.102988_bib6","article-title":"Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance","volume":"383","author":"Yap","year":"2023","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib7","doi-asserted-by":"crossref","first-page":"e1000217","DOI":"10.1371\/journal.pmed.1000217","article-title":"Guidance for developers of health research reporting guidelines","volume":"7","author":"Moher","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.eclinm.2024.102988_bib8","article-title":"Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance","volume":"383","author":"Yap","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102988_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2024.102988_bib10","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2024.102988_bib14","author":"Hayward"},{"issue":"27","key":"10.1016\/j.eclinm.2024.102988_bib15","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"10.1016\/j.eclinm.2024.102988_bib17","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1200\/JCO.21.02125","article-title":"Ethical considerations for phase I trials in oncology","volume":"40","author":"Bittlinger","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102988_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ymeth.2020.01.011","article-title":"In silico trials: verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products","volume":"185","author":"Viceconti","year":"2021","journal-title":"Methods"},{"issue":"10301","key":"10.1016\/j.eclinm.2024.102988_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.eclinm.2024.102988_bib25","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1158\/1078-0432.CCR-06-2860","article-title":"Trends in the use and role of biomarkers in phase I oncology trials","volume":"13","author":"Goulart","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102988_bib26","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4155\/bio-2018-0006","article-title":"Biomarkers in early-phase trials: fundamental issues","volume":"10","author":"Yee","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.eclinm.2024.102988_bib28","series-title":"Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories","year":"2007"},{"key":"10.1016\/j.eclinm.2024.102988_bib29","series-title":"Biomarkers related to drug or biotechnology product development: context, structure and format of qualification submissions","year":"2010"},{"key":"10.1016\/j.eclinm.2024.102988_bib30","series-title":"Guideline on genomic sampling and management of genomic data","year":"2017"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102988_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105359","article-title":"Determining maximal tolerable aerobic training intensity in the acute phase after stroke: a novel dose ranging trial protocol","volume":"29","author":"Kramer","year":"2020","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jclinepi.2007.04.015","article-title":"Cluster randomized trials produced similar results to individually randomized trials in a meta-analysis of enhanced care for depression","volume":"61","author":"Gilbody","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2024.102988_bib37","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.annonc.2022.01.018","article-title":"53P Assessing the reporting quality of early phase dose-finding trials","volume":"33","author":"Yap","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102988_bib38","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3390\/cancers14061566","article-title":"A\u00a0brief overview of adaptive designs for phase I cancer trials","volume":"14","author":"Saxena","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eclinm.2024.102988_bib40","doi-asserted-by":"crossref","first-page":"m115","DOI":"10.1136\/bmj.m115","article-title":"The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design","volume":"369","author":"Dimairo","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2024.102988_bib42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-2288-14-84","article-title":"Three steps to writing adaptive study protocols in the early phase clinical development of new medicines","volume":"14","author":"Lorch","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eclinm.2024.102988_bib43","author":"Henlix"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102988_bib44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12874-018-0638-z","article-title":"How to design a dose-finding study using the continual reassessment method","volume":"19","author":"Wheeler","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eclinm.2024.102988_bib46","article-title":"Model-assisted designs for early-phase clinical trials: simplicity meets superiority","volume":"3","author":"Yuan","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eclinm.2024.102988_bib47","article-title":"Handling incomplete or late-onset toxicities in early-phase dose-finding clinical trials: current practice and future prospects","volume":"8","author":"Yin","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eclinm.2024.102988_bib48","doi-asserted-by":"crossref","first-page":"e068177","DOI":"10.1136\/bmj-2021-068177","article-title":"Early phase clinical trials extension to guidelines for the content of statistical analysis plans","volume":"376","author":"Homer","year":"2022","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/sim.6910","article-title":"Implementation of adaptive methods in early-phase clinical trials","volume":"36","author":"Petroni","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2024.102988_bib52","series-title":"Tolerability and PK of GB1211 in healthy subjects [protocol]","article-title":"A\u00a0first in human study to evaluate the safety","year":"2018"},{"key":"10.1016\/j.eclinm.2024.102988_bib53","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.2147\/DDDT.S121520","article-title":"Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013","volume":"10","author":"Suh","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/cts.12582","article-title":"Design and conduct considerations for first-in-human trials","volume":"12","author":"Shen","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.yrtph.2010.06.007","article-title":"Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals","volume":"58","author":"Tibbitts","year":"2010","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib57","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European medicines agency review of kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.eclinm.2024.102988_bib58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.07.006","article-title":"Clinical development of cell therapies for cancer: the regulators' perspective","volume":"138","author":"Exley","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102988_bib61","first-page":"277","article-title":"Adaptive designs for dual-agent phase I dose-escalation studies","volume":"10","author":"Harrington","year":"2013","journal-title":"Nat\u00a0Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102988_bib62","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdu516","article-title":"Designs of drug-combination phase I trials in oncology: a systematic review of the literature","volume":"26","author":"Riviere","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102988_bib63","doi-asserted-by":"crossref","first-page":"E818","DOI":"10.1016\/S2352-3026(21)00273-8","article-title":"Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study","volume":"8","author":"Rutherford","year":"2021","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib65","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pst.1801","article-title":"Statistical issues in first-in-human studies on BIA 10-2474: neglected comparison of protocol against practice","volume":"16","author":"Bird","year":"2017","journal-title":"Pharm Stat"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102988_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033009","article-title":"Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol","volume":"10","author":"Kong","year":"2020","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102988_bib69","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0091270003252243","article-title":"Evaluation of the cohort size in phase I dose escalation trials based on laboratory data","volume":"43","author":"Bu\u00f6en","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib70","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12885-019-6121-3","article-title":"Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib","volume":"19","author":"de Haan","year":"2019","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102988_bib73","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.eclinm.2024.102988_bib75","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1200\/JCO.22.00371","article-title":"Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients","volume":"40","author":"Fourie Zirkelbach","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib76","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/sim.6894","article-title":"Sequential monitoring of Phase I dose expansion cohorts","volume":"36","author":"Iasonos","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2024.102988_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106605","article-title":"Controlled backfill in oncology dose-finding trials","volume":"111","author":"Dehbi","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102988_bib78","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.18.00889","article-title":"Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102988_bib79","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.clinthera.2016.03.028","article-title":"Safety, tolerability, pharmacokinetic and pharmacodynamic properties of SBI-087, a CD20-directed B-cell depleting agent: phase 1 dose escalating studies in patients with either mild rheumatoid arthritis or systemic lupus","volume":"38","author":"Cohen","year":"2016","journal-title":"Clin Ther"},{"issue":"mar07 3","key":"10.1016\/j.eclinm.2024.102988_bib80","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2024.102988_bib81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102988_bib82","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-016-2189-8","article-title":"Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials","volume":"73","author":"Breithaupt-Groegler","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib84","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12885-022-09272-2","article-title":"Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I\/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma","volume":"22","author":"Mizutani","year":"2022","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.eclinm.2024.102988_bib85","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib87","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bcp.12344","article-title":"Bayesian adaptive designs in single ascending dose trials in healthy volunteers","volume":"78","author":"Guede","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102988_bib88","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/pst.1818","article-title":"Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy","volume":"16","author":"Yeung","year":"2017","journal-title":"Pharm Stat"},{"issue":"28","key":"10.1016\/j.eclinm.2024.102988_bib89","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1002\/sim.8361","article-title":"A\u00a0utility-based Bayesian optimal interval (U-BOIN) phase I\/II design to identify the optimal biological dose\u00a0for targeted and immune therapies","volume":"38","author":"Zhou","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2024.102988_bib90","author":"NanOlogy"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102988_bib92","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd.2017.65","article-title":"Trial watch: trends in clinical trial design complexity","volume":"16","author":"Getz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.eclinm.2024.102988_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106517","article-title":"Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols","volume":"108","author":"Wages","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib95","article-title":"Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)","volume":"9","author":"Slingluff","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"26","key":"10.1016\/j.eclinm.2024.102988_bib96","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020458","article-title":"Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: an early phase trial","volume":"99","author":"Siebert","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.eclinm.2024.102988_bib99","article-title":"Two-stage single-arm trials are rarely analyzed effectively or reported adequately","volume":"5","author":"Grayling","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102988_bib100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0928-0987(01)00096-3","article-title":"Role of modelling and simulation in phase I drug development","volume":"13","author":"Aarons","year":"2001","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102988_bib103","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/15459683211019362","article-title":"Multidimensional phase I dose ranging trials for stroke recovery interventions: key challenges and how to address them","volume":"35","author":"Dalton","year":"2021","journal-title":"Neurorehabilitation Neural Repair"},{"key":"10.1016\/j.eclinm.2024.102988_bib104","series-title":"Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials E9(R1)","year":"2019"},{"key":"10.1016\/j.eclinm.2024.102988_bib105","first-page":"1","article-title":"Estimands in oncology early clinical development: assessing the impact of intercurrent events on the dose-toxicity relationship","author":"Mercier","year":"2024","journal-title":"Stat Biopharm Res"},{"issue":"25","key":"10.1016\/j.eclinm.2024.102988_bib108","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102988_bib112","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib113","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13063-021-05384-5","article-title":"TRAFIC: statistical design and\u00a0analysis plan for a pragmatic early phase 1\/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis","volume":"22","author":"Cole","year":"2021","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12874-017-0381-x","article-title":"Implementing the EffTox dose-finding design in the Matchpoint trial","volume":"17","author":"Brock","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102988_bib116","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/ijerph18010345","article-title":"Using an interaction parameter in model-based phase I trials for combination treatments? A simulation study","volume":"18","author":"Mozgunov","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102988_bib117","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.1158\/1078-0432.CCR-17-0582","article-title":"Dose transition pathways: the missing link between complex dose-finding designs and simple decision-making","volume":"23","author":"Yap","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.eclinm.2024.102988_bib118","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1200\/JCO.2012.45.7903","article-title":"Modified toxicity probability interval design: a safer and more reliable method than the 3\u00a0+ 3 design for practical phase I trials","volume":"31","author":"Ji","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102988_bib119","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/rssc.12089","article-title":"Bayesian optimal interval designs for phase I clinical trials","volume":"64","author":"Liu","year":"2015","journal-title":"J\u00a0Roy Stat Soc C Appl Stat"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T20:10:26Z","timestamp":1750450226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024005674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":78,"alternative-id":["S2589537024005674"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102988","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102988"}}